Medarex, Massachusetts Biologic Labs begin phase 2 trial in diarrhea

By Lisa Kerner

Charlotte, N.C., Sept. 6 - Medarex, Inc. and The Massachusetts Biologic Laboratories began a randomized, double-blind, placebo-controlled phase 2 clinical trial of CDA-1 (or MDX-066) and MDX-1388 for the treatment of C. difficile-associated diarrhea.

Up to 200 patients with the illness will be enrolled in the single-dose trial of the two novel fully human monoclonal antibodies.

"C. difficile-associated diarrhea is a growing and potentially serious epidemic, particularly in the 20% to 50% of hospitalized patients who relapse after receiving antibiotic treatment," Massachusetts Biologic Laboratories director Donna Ambrosino said in a news release.

Medarex is a Princeton, N.J., biopharmaceutical company. Massachusetts Biologic Laboratories is part of the University of Massachusetts Medical School in Jamaica Plain, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.